AbCellera Biologics Inc. (Nasdaq: ABCL) reported its financial results for the third quarter of 2026 on November 9, 2026. The clinical-stage biotechnology company announced a net loss of $40.8 million for the quarter, a decrease compared to a net loss of $57.1 million in the same period of the prior year.
According to the company’s condensed consolidated statements of loss, total revenue for Q3 2026 was $10.6 million, driven by research fees of $10.5 million and licensing and royalty revenue of $90,000. Operating expenses decreased to $63.9 million from $85.2 million in Q3 2025, attributed to lower research and development costs of $43.5 million and a reduction in sales, general, and administrative expenses to $13.6 million.
On the operational front, AbCellera disclosed positive top-line data for its investigational antibody candidate ABCL635 in a Phase 2 clinical trial. The data demonstrated significant reductions in the frequency and severity of vasomotor symptoms (VMS) and favorable tolerability. The company plans to initiate late-stage development for menopausal VMS in 2027 and expand indications to include VMS caused by hormone suppression in breast and prostate cancer treatment.
In a separate announcement, AbCellera completed a $200 million offering of common shares and pre-funded warrants. Following this capital raise and the availability of non-dilutive government funding, the company reported total available liquidity of over $890 million. This figure includes over $790 million in cash, cash equivalents, and marketable securities.
The company also highlighted the advancement of three new pipeline programs—ABCL992, ABCL385, and ABCL646—through IND-enabling activities. Additionally, AbCellera announced top-line data for the Phase 1 clinical trial of ABCL575, an antibody targeting OX40 ligand for atopic dermatitis, which met all endpoints. The company stated it does not currently plan to advance ABCL575 past Phase 1.
